Oryzon Genomics


Contact information

Emili Torrell, BD Spain// Saikat Nandi, Global BD
C / Sant Ferran 74
Cornellà de Llobregat
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Drug development
    • Therapeutic areas
      • Oncology
      • Central nervous system

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.

Our business model is to develop our proprietary drug candidates through clinical Phase II, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization.

Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.

Products and services

Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation.

Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases.

Areas of interest for future collaborations

Oryzon is interested in establishing collaboration or license agreements with pharmaceutical companies to accelerate clinical development and, if possible, shorten the time to market approval of its clinical candidate compounds.

The company is also interested in strategic R&D collaborations to advance its epigenetic scientific platform and its product development strategy.